Company Profile
ProQR Therapeutics Stock Price, News & Analysis
- Ticker:
- PRQR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Netherlands and listed in the U
Stock performance
1.90 USD (-3.55%)
Close
Last updated: August 6, 2026
155M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, PRQR closed down 3.55% at $1.90. No new same-company headline was identified in the current news window.
Company overview
RNA Editing Company
ProQR Therapeutics develops RNA-editing medicines using its Axiomer platform.
Axiomer Technology
Axiomer recruits endogenous ADAR enzymes to make precise single-base changes in RNA without permanently altering DNA.
AX-0810
AX-0810 targets NTCP and is being developed initially for biliary atresia, with early clinical work measuring target engagement in healthy volunteers.
Pipeline Expansion
Additional programs include AX-0811 and IDUA-targeting AX-0422, supported by internal and partnered discovery capabilities.
Future catalysts
AX-0810 target-engagement data from healthy volunteers are expected in the second quarter of 2026.
ProQR plans an investigator-initiated pediatric Phase 2 study of AX-0810 in biliary atresia.
Recent news
- 01
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
Source: ProQR Therapeutics
- 02
- 03
ProQR Announces First Quarter 2026 Operating and Financial Results
Source: ProQR Therapeutics
- 04
- 05
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
Source: ProQR Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of ProQR Therapeutics (PRQR)?
ProQR Therapeutics (PRQR) most recently closed at 1.90 USD, a -3.55% move versus the previous session.
What is the market cap of ProQR Therapeutics (PRQR)?
ProQR Therapeutics currently has a market capitalization of 155M USD on BioPharmSignal.
What does ProQR Therapeutics do?
RNA Editing Company ProQR Therapeutics develops RNA-editing medicines using its Axiomer platform. Axiomer Technology Axiomer recruits endogenous ADAR enzymes to make precise single-base changes in RNA without permanently altering DNA. AX-0810 AX-0810 targets NTCP and is being developed initially for biliary atresia, with early clinical work measuring target...
On which exchange is PRQR stock listed?
ProQR Therapeutics (PRQR) is associated with NASDAQ, Netherlands and listed in the U, Biopharma.
What is AX-0810?
AX-0810 target-engagement data from healthy volunteers are expected in the second quarter of 2026.
Which conditions is ProQR Therapeutics targeting with AX-0810?
AX-0810 target-engagement data from healthy volunteers are expected in the second quarter of 2026.
How does ProQR Therapeutics describe recent progress with AX-0810?
AX-0810 target-engagement data from healthy volunteers are expected in the second quarter of 2026.
What is AX-0811?
Pipeline Expansion Additional programs include AX-0811 and IDUA-targeting AX-0422, supported by internal and partnered discovery capabilities.